Proof-of-Concept Study Finds Feasibility, Not Clinical Utility of Gastric Cancer Genomic Classifier

NEW YORK (GenomeWeb) – Even though the authors of a new study were unable to establish the clinical utility of the gastric cancer genomic classifier they were evaluating, they said their results still showed that gene expression profiling could help guide treatment.

A team of researchers led by the National University of Singapore’s Patrick Tam sought to assess whether previously reported intrinsic gene expression signatures could help tailor gastric cancer treatment. In Gastroenterology in 2011, the team reported on its finding of two gastric cancer subtypes with distinct gene expression patterns that were associated with chemotherapy response and patient survival.

In their new study, the researchers examined whether those intrinsic gene expression signatures could predict chemotherapy benefit. As they reported in Clinical Cancer Research yesterday, they found no demonstrable clinical utility of this classifier. However, a metabolic classifier they also examined looked promising.

“Importantly, this proof-of-concept study demonstrated that prospective gene-expression profiling to guide treatment selection is feasible and can yield potentially actionable results with a reasonable turnaround timeframe,” Tam and his colleagues wrote in their paper.

The previously reported intrinsic gene expression signature — which is based on 171 genes — divides gastric cancers into two groups: G-intestinal (G1) or

Be the first to comment

Leave a Reply

Your email address will not be published.